Recurrent Miscarriage Clinical Trial
Official title:
A Double-Blind, Randomized, Placebo-Controlled Study of GB-0998 in Patients With Unexplained Recurrent Miscarriage.
NCT number | NCT02184741 |
Other study ID # | B211-11 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | June 3, 2014 |
Est. completion date | September 2020 |
Verified date | October 2021 |
Source | Japan Blood Products Organization |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The present survey was conducted to evaluate the efficacy and safety of GB-0998(immunoglobulin) in the treatment of unexplained recurrent miscarriage in comparison to placebo using a multicenter, double-blind, intergroup comparison method.
Status | Completed |
Enrollment | 99 |
Est. completion date | September 2020 |
Est. primary completion date | May 2020 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A to 41 Years |
Eligibility | Inclusion Criteria 1. Patients with primary recurrent miscarriage 2. Patients with a history of at least 4 miscarriages (not including biochemical pregnancy in the count of prior miscarriages) 3. Patients with any of the following risk factors for recurrent miscarriage ?Patients with unknown risk factors? Patients with normal test results for each of the following risk factors who have experienced miscarriage of a fetus with normal chromosome karyotype 1. Abnormal uterine morphology 2. Thyroid dysfunction 3. Chromosome abnormality in the couple 4. Positive antiphospholipid antibody 5. Factor XII deficiency 6. Protein S deficiency 7. Protein C deficiency ?Patients determined to have risk factors? Patients with the following risk factors who have experienced miscarriage of a fetus with normal chromosome karyotype despite receiving treatment for these factors 1. Abnormal uterine morphology (septate uterus): Patients who have undergone surgery 2. Thyroid dysfunction: Patients receiving medical treatment 3. Incidentally positive antiphospholipid antibody, factor XII deficiency, protein S deficiency, protein C deficiency:Patients receiving combination therapy with aspirin and heparin 4.Regardless of whether or not risk factors are present, patients should have experienced at least 1 a miscarriage of a fetus with normal chromosome karyotype 5.Patients below the age of 42 years at the time of obtaining informed consent 6.Patients who can be admitted for at least the period from the start date of administration of the study drug to the date of examination and assessment 1 week after the start of administration of the study drug 7.Patients who have given written informed consent to participate in this study Exclusion Criteria: 1. Patients with chromosome abnormalities in themselves or their partners that are risk factors for recurrent miscarriage, patients with antiphospholipid syndrome, and patients with incidentally positive antiphospholipid antibody (when the latest test result is positive) 2. Patients in whom complications of diabetes mellitus or impaired glucose tolerance has been identified, but who have not received appropriate treatment for this condition 3. Patients who have received intravenous immunoglobulin therapy as treatment for recurrent miscarriage in the past 4. Patients with a history of stillbirth at 22 weeks of gestation or later 5. Patients receiving treatment for malignant tumor 6. Patients with a history of thromboembolism 7. Patients with a history of shock or hypersensitivity in response to the ingredients of this drug or patients with hereditary fructose intolerance 8. Patients who have been diagnosed with IgA deficiency in the past or patients who have a serum IgA level of <5 mg/dL at laboratory tests at registration 9. Patients who have received another study drug within the period of 12 weeks prior to informed consent or who are currently participating in another clinical trial 10. Patients who are unsuitable for this study for any other reason, in the opinion of a principal investigator or sub-investigators |
Country | Name | City | State |
---|---|---|---|
Japan | Japan Blood Products Organization | Tokyo |
Lead Sponsor | Collaborator |
---|---|
Japan Blood Products Organization |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Ongoing pregnancy rate (excluding miscarriages associated with fetal chromosomal abnormalities) | To evaluate the effectiveness of the drug in preventing miscarriages, we examined the ongoing pregnancy rate at 22 weeks and 0 days of gestation in cases excluding cases of fetal chromosome aberration miscarriages. | At 22 weeks of gestation | |
Secondary | Ongoing pregnancy rate(all patients) | To evaluate the effectiveness of the drug in preventing miscarriages, we examined the ongoing pregnancy rate at 22 weeks and 0 days of gestation in all patients. | At 22 weeks of gestation | |
Secondary | Live birth rate (excluding miscarriages associated with fetal chromosomal abnormalities) | To evaluate the effectiveness of the drug in total outcome of pregnancy, we examined the live birth rate in cases excluding cases of fetal chromosome aberration miscarriages. | At the time of birth | |
Secondary | Live birth rate(all patients) | To evaluate the effectiveness of the drug in total outcome of pregnancy, we examined the live birth rate in all patients. | At the time of birth |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01419392 -
Role of Sildenafil Citrate in Patients With Unexplained Recurrent Miscarriages
|
Phase 4 | |
Completed |
NCT00193674 -
Habitual Abortion Study: Oral Dydrogesterone Treatment During Pregnancy in Women With Recurrent Miscarriage
|
Phase 3 | |
Completed |
NCT06001060 -
Distinct Alterations in Gut Microbiota Composition Among Women of Reproductive Age With Elevated Homocysteine Levels.
|
||
Recruiting |
NCT05034250 -
Iron Status in Female Infertility and Recurrent Miscarriage
|
||
Completed |
NCT02681627 -
Sim (Scratch in Miscarriage) Study
|
N/A | |
Recruiting |
NCT02303171 -
Use of Warfarin After the First Trimester in Pregnant Women With APS
|
Phase 4 | |
Completed |
NCT02305420 -
EmbryoGen/ Blastgen for Couples With Implantation Problems or Previous Miscarriage
|
Phase 4 | |
Recruiting |
NCT05824897 -
The Cohort Study of the Correlation Between Serum 25(OH)D Level and Pregnancy Outcome
|
||
Completed |
NCT03023137 -
Walking and Dietary Modification for Recurrent Early Miscarriages
|
N/A | |
Not yet recruiting |
NCT03132779 -
Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortion
|
Phase 1 | |
Active, not recruiting |
NCT02156063 -
A Multi-center, Placebo-controlled Study to Evaluate NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL)
|
Phase 2 | |
Recruiting |
NCT03902912 -
Effect of Prednisolone Treatment on Uterine Natural Killer Cells
|
Phase 3 | |
Not yet recruiting |
NCT03209063 -
The Role of Prothrombin Gene and Methylenetetrahydrofolate Reductase(MTHFR) Gene Polymorphisms as Risk Factors for Recurrent Miscarriage
|
||
Completed |
NCT03970954 -
Low-dose Interleukin-2 in Women With Unexplained Miscarriages
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06249230 -
The Analysis of Risk Factors for Recurrent Pregnancy Loss and Prediction of Pregnancy Loss Risk
|
||
Recruiting |
NCT05725512 -
Prednisolone Administration in Patients With Unexplained REcurrent MIscarriages
|
Phase 4 | |
Recruiting |
NCT05267678 -
Nutritional Deficiency and Recurrent Miscarriage
|
||
Completed |
NCT02504281 -
Study on the Association Between SXCI and RM and the Possible Genetic Mechanism
|
||
Completed |
NCT02694367 -
Expression of EPK in Recurrent Miscarriage
|
N/A | |
Completed |
NCT01608347 -
Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies
|
Phase 4 |